scholarly journals IgG and IgA Antibodies Post SARS-CoV-2 Vaccine in the Breast Milk and Sera of Breastfeeding Women

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 125
Author(s):  
Federica Scrimin ◽  
Giuseppina Campisciano ◽  
Manola Comar ◽  
Chiara Ragazzon ◽  
Riccardo Davanzo ◽  
...  
Keyword(s):  
Breast Milk ◽  
Vaccination Campaign ◽  
Vaccine Dose ◽  
Primary Objective ◽  
Maternal Serum ◽  
Igg Antibodies ◽  
Maternal Vaccination ◽  
Dose Information ◽  
Sample Testing ◽  
Sera Samples

The COVID-19 pandemic has carried massive global health and economic burden that is currently counteracted by a challenging anti-COVID-19 vaccination campaign. Indeed, mass vaccination against COVID-19 is expected to be the most efficacious intervention to mitigate the pandemic successfully. The primary objective of the present study is to test the presence of neutralizing anti-SARS-CoV-2 antibodies (IgA and IgG) in the breast milk and sera samples from vaccinated women at least 20 days after the complete vaccine cycle. A secondary aim is to compare the IgG antibodies level in maternal serum and breast milk. The third target is to evaluate the presence of the IgG antibodies in breast milk after several weeks from the vaccination. Finally, we collected information on the health status of infants in the days following maternal vaccination. Forty-two mothers were enrolled in the study. Thirty-six received the Pfizer/BioNTech vaccine, four the Astra Zeneca vaccine, one the Moderna vaccine and another woman Astra Zeneca in the first dose and Pfizer/BioNTech in the second dose. All 42 milk samples confirmed the presence of anti-SARS-CoV-2 IgG, and none showed IgA presence. Regarding the matched 42 sera samples, 41 samples detected IgG presence, with one sample testing negative and only one positive for seric IgA. None of the 42 infants had fever or changes in sleep or appetite in the seven days following the maternal vaccination. The level of IgG antibodies in milk was, on average, lower than that in maternal serum. According to our analysis, the absence of IgA could suggest a rapid decrease after vaccination even if frequent breastfeeding could favour its persistence. IgG were present in breast milk even 4 months after the second vaccine dose. Information on the immunological characteristics of breast milk could change mothers’ choices regarding breastfeeding.

scholarly journals Impact of Maternal Daily Oral Low-Dose Vitamin A Supplementation on the Mother–Infant Pair: A Randomised Placebo-Controlled Trial in China

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2370
Author(s):  
Ye Ding ◽  
Ping Hu ◽  
Yue Yang ◽  
Fangping Xu ◽  
Fang Li ◽  
...  
Keyword(s):  
Health Status ◽  
Breast Milk ◽  
Vitamin A ◽  
Low Dose ◽  
Maternal Serum ◽  
Control Group ◽  
Vitamin A Supplementation ◽  
Maternal Vitamin ◽  
Vitamin A Status ◽  
Lactating Mothers

Background: The nutritional status of vitamin A in lactating mothers and infants is still not optimistic. Due to the dietary habits and dietary restrictions of postpartum customs in China, vitamin A supplementation has been advocated as a potential strategy to improve vitamin A status of lactating mothers with inadequate dietary vitamin A intake. Existing clinical trials are limited to single or double high-dose maternal administrations. However, in China, vitamin A supplements are readily available in the form of daily oral low-dose supplements, and the effect of these is unknown. This study aimed to evaluate the effects of daily oral low-dose vitamin A supplementation on the retinol levels in the serum and breast milk of lactating mothers and the health status of infants in China. Methods: Lactating mothers who met the inclusion criteria and planned to continue exclusive breastfeeding were randomly assigned to receive either daily oral vitamin A and D drops (one soft capsule of 1800 IU vitamin A and 600 IU vitamin D2), or a matching placebo for 2 months. Before and after the intervention, dietary intake was investigated by instant photography, and the retinol concentration in maternal serum and breast milk was determined by ultra-high performance liquid chromatography-tandem mass spectrometry. During the trial, the health status of infants was diagnosed by a paediatrician or reported by lactating mothers. A total of 245 participants completed the study, with 117 in the supplementation group and 128 in the control group. Results: After the 2-month intervention, maternal serum retinol concentrations increased in the supplementation group with no change in the control group. Although breast milk retinol concentrations decreased significantly in both groups, the decrease in the supplementation group was significantly lower than that in the control group. However, maternal vitamin A supplementation was not associated with a lower risk of infant febrile illness, respiratory tract infection, diarrhoea, and eczema. Conclusions: Daily oral low-dose vitamin A supplementation is helpful in improving maternal vitamin A status, despite having no effect on infant health status through breast milk.

Eplerenone levels in maternal serum, cord blood, and breast milk during pregnancy and lactation

2021 ◽  
Author(s):  
Jumpei Saito ◽  
Asako Mito ◽  
Naho Yakuwa ◽  
Kayoko Kaneko ◽  
Hiroyo Kawasaki ◽  
...  
Keyword(s):  
Breast Milk ◽  
Cord Blood ◽  
Maternal Serum ◽  
Pregnancy And Lactation

scholarly journals Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol

Pathogens ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 911
Author(s):  
Marie Pouquet ◽  
Dorine Decarreaux ◽  
Pol Prévot-Monsacré ◽  
Corentin Hervé ◽  
Andréas Werner ◽  
...  
Keyword(s):  
Health Care ◽  
Primary Health Care ◽  
Health Care Workers ◽  
Phase 1 ◽  
Vaccination Campaign ◽  
Igg Antibodies ◽  
Household Contacts ◽  
Primary Health ◽  
Care Workers ◽  
Natural Protection

Background: The protocol study will focus on the seroprevalence of IgG antibodies to SARS-CoV-2 achieved by vaccination and/or natural protection as well as the history, symptoms, and risk factors for SARS-CoV-2 in four primary health-care workers (PHCWs) and their household contacts in metropolitan France. Methods: Here, we propose a protocol for a nationwide survey to determine the seroprevalence of IgG antibodies to SARS-CoV-2 achieved by vaccination and/or natural protection in four PHCW populations (general practitioners, pediatricians, pharmacists and assistants, and dentists and assistants) and their household contacts. Participants will be included from June to July 2021 (Phase 1) among PHCW populations located throughout metropolitan France. They will be asked to provide a range of demographic and behavioral information since the first SARS-CoV-2 wave and a self-sampled dried blood spot. Phase 1 will involve also a questionnaire and serological study of PHCWs’ household contacts. Seroprevalence will be estimated using two ELISAs designed to detect specific IgG antibodies to SARS-CoV-2 in humoral fluid, and these results will be confirmed using a virus neutralization test. This study will be repeated from November to December 2021 (Phase 2) to evaluate the evolution of immune status achieved by vaccination and/or natural protection of PHCWs and to describe the history of exposure to SARS-CoV-2.

scholarly journals Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand

Vaccines ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 3
Author(s):  
Zoltán Kis ◽  
Cleo Kontoravdi ◽  
Robin Shattock ◽  
Nilay Shah
Keyword(s):  
Production Process ◽  
Messenger Rna ◽  
Vaccination Campaign ◽  
Vaccine Dose ◽  
Economic Feasibility ◽  
Small Scale ◽  
Production Scale ◽  
Working Volume ◽  
Global Demand ◽  
The Impact

To overcome pandemics, such as COVID-19, vaccines are urgently needed at very high volumes. Here we assess the techno-economic feasibility of producing RNA vaccines for the demand associated with a global vaccination campaign. Production process performance is assessed for three messenger RNA (mRNA) and one self-amplifying RNA (saRNA) vaccines, all currently under clinical development, as well as for a hypothetical next-generation saRNA vaccine. The impact of key process design and operation uncertainties on the performance of the production process was assessed. The RNA vaccine drug substance (DS) production rates, volumes and costs are mostly impacted by the RNA amount per vaccine dose and to a lesser extent by the scale and titre in the production process. The resources, production scale and speed required to meet global demand vary substantially in function of the RNA amount per dose. For lower dose saRNA vaccines, global demand can be met using a production process at a scale of below 10 L bioreactor working volume. Consequently, these small-scale processes require a low amount of resources to set up and operate. RNA DS production can be faster than fill-to-finish into multidose vials; hence the latter may constitute a bottleneck.

scholarly journals Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice

Vaccines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 316
Author(s):  
Ki-Hye Kim ◽  
Noopur Bhatnagar ◽  
Subbiah Jeeva ◽  
Judy Oh ◽  
Bo Ryoung Park ◽  
...  
Keyword(s):  
Young Adult ◽  
Receptor Binding ◽  
Vaccine Dose ◽  
The Elderly ◽  
Full Length ◽  
High Dose ◽  
Igg Antibodies ◽  
Neutralizing Activity ◽  
Aged Mice ◽  
Adjuvant Effects

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be expanding the pandemic disease across the globe. Although SARS-CoV-2 vaccines were rapidly developed and approved for emergency use of vaccination in humans, supply and production difficulties are slowing down the global vaccination program. The efficacy of many different versions of vaccine candidates and adjuvant effects remain unknown, particularly in the elderly. In this study, we compared the immunogenic properties of SARS-CoV-2 full-length spike (S) ectodomain in young adult and aged mice, S1 with receptor binding domain, and S2 with fusion domain. Full-length S was more immunogenic and effective in inducing IgG antibodies after low dose vaccination, compared to the S1 subunit. Old-aged mice induced SARS-CoV-2 spike-specific IgG antibodies with neutralizing activity after high dose S vaccination. With an increased vaccine dose, S1 was highly effective in inducing neutralizing and receptor-binding inhibiting antibodies, although both S1 and S2 subunit domain vaccines were similarly immunogenic. Adjuvant effects were significant for effective induction of IgG1 and IgG2a isotypes, neutralizing and receptor-binding inhibiting antibodies, and antibody-secreting B cell and interferon-γ secreting T cell immune responses. Results of this study provide information in designing SARS-CoV-2 spike vaccine antigens and effective vaccination in the elderly.

scholarly journals Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose

2021 ◽  
Author(s):  
Merav Mofaz ◽  
Matan Yechezkel ◽  
Grace Guan ◽  
Margaret L. Brandeau ◽  
Tal Patalon ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Booster Dose ◽  
Vaccination Campaign ◽  
Vaccine Dose ◽  
P Value ◽  
Booster Vaccine ◽  
The Third ◽  
Systemic Reactions ◽  
Physiological Reactions

AbstractBackgroundThe rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to initialize a national third (booster) COVID-19 vaccination campaign in early August 2021, offering the BNT162b2 mRNA vaccine to individuals who received their second dose over five months ago. However, the safety of the third (booster) dose has not been fully established yet.ObjectiveEvaluate the short-term, self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose.DesignA prospective observational study, in which participants are equipped with a smartwatch and fill in a daily questionnaire via a dedicated mobile application for a period of 21 days, starting seven days before the vaccination.SettingAn Israel-wide third (booster) vaccination campaign.ParticipantsA group of 1,609 (18+ years of age) recipients of at least one dose of the BNT162b2 vaccine between December 20, 2020, and September 15, 2021, out of a larger cohort of 2,912 prospective study participants. 1,344 of the participants were recipients of the third vaccine dose.MeasurementsDaily self-reported questionnaires regarding local and systemic reactions, mood level, stress level, sport duration, and sleep quality. Heart rate, heart rate variability and blood oxygen saturation level were continuously measured by Garmin Vivosmart 4 smartwatches.ResultsThe extent of systemic reactions reported following the third (booster) dose administration is similar to that reported following the second dose (p-value=0.305) and considerably greater than that reported following the first dose (p-value<0.001). Our analyses of self-reported well-being indicators as well as the objective heart rate and heart rate variability measures recorded by the smartwatches further support this finding. Focusing on the third dose, reactions were more apparent in younger participants (p-value<0.01), in women (p-value<0.001), and in participants with no underlying medical conditions (p-value<0.001). Nevertheless, reported reactions and changes in physiological measures returned to their baseline levels within three days from inoculation with the third dose.LimitationsParticipants may not adequately represent the vaccinated population in Israel and elsewhere.ConclusionOur work further supports the safety of a third COVID-19 BNT162b2 mRNA (booster) vaccine dose from both a subjective and an objective perspective, particularly in individuals 65+ years of age and those with underlying medical conditions.Primary funding sourceEuropean Research Council (ERC) project #949850

scholarly journals Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Davide Ferrari ◽  
Alessandra Mangia ◽  
Maria Sestina Spanò ◽  
Lucia Zaffarano ◽  
Marco Viganò ◽  
...  
Keyword(s):  
Immune Response ◽  
General Population ◽  
Serological Test ◽  
Vaccination Campaign ◽  
Age Groups ◽  
Vaccine Dose ◽  
Serum Samples ◽  
Serological Tests ◽  
Antibody Persistence ◽  
Definition Of

Abstract Objectives After exceptional research efforts, several vaccines were developed against SARS-CoV-2 which sustains the pandemic COVID-19. The Comirnaty vaccine showed high efficacy in clinical trials and was the first to be approved for its distribution to the general population. We evaluated the immune response induced by the first vaccine dose in different sex/age groups and subjects with or without naturally present anti-SARS-CoV-2 antibodies. Methods As part of an Italian multicenter project (Covidiagnostix), serum samples from 4,290 health-professionals were serologically tested the day of the first vaccination dose, and 21 days later, using two different instrumentations (Siemens-Healthineers and Roche). Results In total, 97% of samples showed the presence of specific antibodies 21 days after the vaccination dose; the percentage of non-responders increased with age in both genders. Remarkably, naturally seropositive individuals showed antibody persistence up to 11 months and an exceptionally higher vaccination response compared to subjects never infected by SARS-CoV-2. Conclusions This study highlighted the importance of the serological test i) to identify naturally SARS-CoV-2 seropositive individuals and ii) to evaluate the antibody level elicited by the first vaccination dose. Both tests, highlighted differences in the immune response, when subjects were stratified by sex and age, and between naturally seropositive and seronegative subjects. The data obtained show how serological tests could play a crucial role in the triage of the population subjected to the vaccination campaign for COVID-19. The definition of suitable instrumentation-specific thresholds is needed to correctly follow eventually acquired post-vaccination immunity in the general population.

scholarly journals Effect of probiotics on stool characteristic of bottle fed infants

2019 ◽  
Vol 9 (3) ◽  
pp. 157
Author(s):  
Yoo Mi Lee ◽  
Young Sun Cho ◽  
Su Jin Jeong
Keyword(s):  
Breast Milk ◽  
South Korea ◽  
Lactobacillus Plantarum ◽  
Medical Center ◽  
Sole Source ◽  
Primary Objective ◽  
Stool Frequency ◽  
Once Daily ◽  
Bristol Stool Scale ◽  
Secondary Objective

Background: Approximately 70% of all newborns in South Korea are fed a commercial formula as their sole source of nutrition or as a supplement to breast milk. It is common for many formula-fed infants to be switched from one formula to another because of perceived abnormalities in stooling patterns (too much/too little, too hard/too loose). Also, probiotics may have been recommended by a clinician or practitioner when there is thought to be a problem with the babies stool based on many reports.Aims: The primary objective of this study was to determine whether probiotic (nLp-nF1) exposure during the first 6 months of life is safe. The secondary objective was to assess if nF1 exposure correlated with changes in formula-fed infants’ stool characteristics.Result: We recruited 49 healthy formula-fed infants aged 0-6 months from Bundang Cha Medical Center. Infants were given a 14-day supply of probiotics (nf1: Lactobacillus plantarum 2.5 X 1010/g/pack, 2 pack/day). The overall rate of stool change after probiotics is 83% (41/49). Among them, 75.6% (31/41) participants answered fairly about the change of stool characteristics. The significant change of stool frequency, stool color and flatulence after probiotics intervention was reported. The number of infants who defecated once daily was increased from 53% (26 of 49) to 77.5% (38 of 49) (P=0.075). Mustard yellow colored feces increased from 22 to 40 (p=0.018). Only 9 out of 20 infants with flatulence (>3 times) showed persistence of symptoms after probiotics (p<0.001). After taking probiotics, Bristol Stool Scale 4-5 stool was reported from 23 to 37(p=0.018).Conclusion: By taking probiotics, the color of the stool changed, and the incidence of flatulence production decreased. Although the results are not statistically significant, the quality and quantity of stool improved according to the Bristol Stool Scale.Keywords: Probiotics, Bristol Stool Scale, stool

scholarly journals Vitamin A intake of Brazilian mothers and retinol concentrations in maternal blood, human milk, and the umbilical cord

2018 ◽  
Vol 46 (4) ◽  
pp. 1555-1569 ◽  
Author(s):  
Thalia Manfrin Martins Deminice ◽  
Ivan Savioli Ferraz ◽  
Jacqueline Pontes Monteiro ◽  
Alceu Afonso Jordão ◽  
Lívia Maria Cordeiro Simões Ambrósio ◽  
...  
Keyword(s):  
Breast Milk ◽  
Vitamin A ◽  
Human Milk ◽  
Pregnant Women ◽  
Umbilical Cord ◽  
Maternal Blood ◽  
Maternal Serum ◽  
Serum Retinol ◽  
Cross Sectional ◽  
Blood Samples

Objectives To analyse intake of vitamin A (VA) and retinol concentrations in maternal blood, breast milk (BM), and the umbilical cord (UC) of newborns, and to determine the associations among these variables. Methods We performed a cross-sectional, epidemiological study of 180 mother–newborn dyads. Maternal and UC blood samples and BM were collected. VA intake by the mother over 30 days was assessed using a questionnaire. Results Mean retinol concentrations in maternal serum, the UC, and BM were 0.65 ± 0.27, 0.36 ± 0.18, and 2.95 ± 2.70 µmol/L, respectively. Retinol concentrations <0.70 µmol/L were found in 57.2% of maternal blood samples and in 94.9% of UC samples. A total of 27.9% of BM samples showed retinol concentrations <1.05 µmol/L. Mean VA intake by the mothers was 1041.33 ± 1187.86 µg retinol activity equivalents/day and was inadequate (<550 µg retinol activity equivalents/day) in 44.7%. Conclusions High proportions of insufficient retinol concentrations were observed in the UC, maternal blood, and BM. A high percentage of pregnant women had inadequate VA intake. Mothers with insufficient serum retinol concentrations had newborns with lower retinol concentrations in the UC. Higher retinol concentrations were observed in maternal blood and the UC with a higher VA intake.

Trazodone Levels in Maternal Serum, Cord Blood, Breast Milk, and Neonatal Serum

2021 ◽  
Author(s):  
Jumpei Saito ◽  
Mariko Ishii ◽  
Asako Mito ◽  
Naho Yakuwa ◽  
Hiroyo Kawasaki ◽  
...  
Keyword(s):  
Breast Milk ◽  
Cord Blood ◽  
Maternal Serum
Sign in / Sign up

Export Citation Format

Share Document